William Blair Has Positive Forecast for APLT FY2025 Earnings

Applied Therapeutics, Inc. (NASDAQ:APLT) – Research analysts at William Blair boosted their FY2025 earnings per share (EPS) estimates for shares of Applied Therapeutics in a report released on Wednesday, May 14th. William Blair analyst S. Corwin now forecasts that the company will earn ($0.64) per share for the year, up from their previous estimate of ($0.66). The consensus estimate for Applied Therapeutics’ current full-year earnings is ($0.65) per share. William Blair also issued estimates for Applied Therapeutics’ FY2026 earnings at ($0.71) EPS.

Applied Therapeutics (NASDAQ:APLT) last posted its quarterly earnings results on Monday, April 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The company had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.61 million.

Separately, Royal Bank of Canada restated a “sector perform” rating and issued a $1.50 target price on shares of Applied Therapeutics in a research note on Wednesday, May 14th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Applied Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $6.10.

Applied Therapeutics Stock Performance

NASDAQ APLT opened at $0.60 on Monday. Applied Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $10.62. The stock has a 50 day simple moving average of $0.43 and a two-hundred day simple moving average of $1.86. The stock has a market cap of $85.36 million, a P/E ratio of -0.37 and a beta of 2.00.

Institutional Investors Weigh In On Applied Therapeutics

A number of hedge funds have recently made changes to their positions in APLT. Vestal Point Capital LP lifted its position in shares of Applied Therapeutics by 904.4% in the fourth quarter. Vestal Point Capital LP now owns 11,500,000 shares of the company’s stock worth $9,846,000 after buying an additional 10,355,000 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its position in shares of Applied Therapeutics by 2,458.3% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 8,762,291 shares of the company’s stock worth $7,502,000 after buying an additional 8,419,781 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Applied Therapeutics by 2,511.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 5,420,920 shares of the company’s stock worth $4,642,000 after buying an additional 5,213,370 shares in the last quarter. Propel Bio Management LLC increased its stake in Applied Therapeutics by 46.4% during the fourth quarter. Propel Bio Management LLC now owns 9,615,420 shares of the company’s stock worth $8,233,000 after acquiring an additional 3,047,562 shares during the last quarter. Finally, Alyeska Investment Group L.P. increased its stake in Applied Therapeutics by 175.8% during the fourth quarter. Alyeska Investment Group L.P. now owns 2,707,497 shares of the company’s stock worth $2,318,000 after acquiring an additional 1,725,824 shares during the last quarter. 98.31% of the stock is currently owned by hedge funds and other institutional investors.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.